Gonadotropin levels are similar in African-American women (AAW) and Caucasian women (CW), despite higher preovulatory estradiol (E2) levels in AAW, suggesting that AAW may be less sensitive to E2 feedback than CW.
R
acial disparities between African-American women (AAW) and Caucasian women (CW) in the incidence of breast cancer (1), leiomyomas (2) , and osteoporosis (3), all of which are estrogen-dependent, suggest that there may be differences in the sex steroid milieu of the two racial groups resulting in a greater lifetime exposure to estrogens in AAW. Our previous studies of daily blood sampling across a full menstrual cycle with growth of a single dominant follicle indeed demonstrated that age-and BMI-matched AAW have higher estradiol (E2) levels than CW during the late follicular phase and luteal phase, but not during the early and mid-follicular phases (4) . Despite higher E2 levels in AAW preceding ovulation, there were no racial differences in gonadotropin levels, suggesting that AAW may be less sensitive to the positive feedback effects of estrogen on the central components of the reproductive axis.
To investigate this hypothesis, we administered an identical sex steroid infusion to AAW and CW during the early follicular phase, when endogenous sex steroids are relatively low. This steroid infusion protocol recreates physiological follicular phase levels of E2 and progesterone (P) and has previously been shown to result in negative feedback followed by positive feedback on gonadotropins (5, 6) . The current studies demonstrate that in the presence of controlled levels of E2, there are no differences in estrogen-positive feedback on LH or FSH between AAW and CW.
Subjects and Methods

Subjects
Healthy, euthyroid, normoprolactinemic AAW (age 22-36 yr; n ϭ 10) and CW (age 23-36 yr; n ϭ 13) were studied. Race was determined by self-report as previously described (4) . All subjects had a history of regular menstrual cycles with an ovulatory cycle preceding participation in the study [P Ͼ 3 ng/ml (9.5 nmol/liter)]. Subjects had no clinical evidence of androgen excess, did not exercise excessively (7) , and were nonsmokers.
The study was approved by the Human Research Committee (HRC) of the Massachusetts General Hospital, and signed informed consent was obtained from each subject. Subjects were recruited from the community by online advertisements and were compensated according to HRC guidelines.
Experimental protocol
Subjects were admitted between d 1 and 6 from menses for a 5-d, graded iv E2 and P infusion study. A stepwise infusion of E2 was initiated on the day of admission and continued for 96 h, as previously described (5, 6, 8) , simulating the rise in E2 that occurs during the follicular phase (Fig. 1 ). An infusion of P was started 48 h after the start of the E2 infusion and continued for 48 h to mimic the low concentrations of P that are present before ovulation. Three blood samples were obtained from each subject at 15-min intervals before the infusion, followed by sampling every 4 h for 5 d. All samples were assayed for LH, FSH, E2, and P. Transvaginal ultrasounds were performed on the first and final days of the study to assess follicular development.
Assays
Serum E2 was measured by immunoassay (AxSYM; Abbott Laboratories, Abbott Park, IL), as previously described (9), with a functional sensitivity of 20 pg/ml (73.4 pmol/liter) and interassay coefficients of variation (CV) of 10.2, 6.5, and 8.2% for quality control sera (QCS) containing 81, 284, and 683 pg/ml (297, 1042, and 2507 pmol/liter), respectively. P was measured using a chemiluminescent enzyme immunoassay (Immulite 1000; Siemens, Los Angeles, CA). The ranges of inter-and intraassay CV for P were 5.8 -16 and 5.0 -16% for concentrations between 0.8 and 33 ng/ml (2.5-104.9 nmol/liter), and the sensitivity was 0.2 ng/ml (0.6 nmol/liter). LH and FSH were measured by a two-site monoclonal nonisotopic system (AxSYM; Abbott Laboratories) as previously described (10) 
Data analysis
Using previously collected data from a group of 18 predominantly Caucasian women undergoing a similar infusion who reached a peak LH of 28.4 Ϯ 8.9 IU/liter (mean Ϯ SD) (6), we determined that 22 women would be necessary to identify a 30% difference in peak LH levels, the primary outcome measure, between AAW and CW with 80% power at a significance level of 0.05.
ANOVA for repeated measures was used to compare absolute E2 and P levels and the percentage increase in E2 and P during each infusion increment between AAW and CW. Baseline LH and FSH were calculated as the arithmetic mean of the three preinfusion samples. The negative-feedback effect of E2 on LH and FSH was assessed by identifying the value and time of the LH and FSH nadir based on a three-point moving average. For each individual, the onset of the LH surge was defined as the time when LH first exceeded the mean ϩ 2 SD values of the previous three time points and showed a sustained increase, as previously described (5, 8) , and the LH peak was defined as the highest value. The area under the curve (AUC) of the positive-feedback response was calculated using the trapezoidal rule. The surge onset, peak, and AUC for FSH were calculated similarly. Unpaired t tests were used to compare baseline values, the negative-feedback response (LH and FSH nadir and time to nadir), and the positive-feedback response (LH and FSH peak, AUC, and time of surge onset) between AAW and CW. Results are expressed as the mean Ϯ SEM unless otherwise indicated, and a P value Ͻ 0.05 was considered statistically significant.
Results
Baseline characteristics
The AAW and CW were of similar age (28.0 Ϯ 0.9 yr) and body mass index (24.2 Ϯ 0.7 kg/m 2 ). Baseline gonadotropins (LH 11.1 Ϯ 0.9 IU/liter, FSH 8.6 Ϯ 1.2 IU/liter), E2 levels [39.7 Ϯ 3.9 pg/ml (145.7 Ϯ 14.4 pmol/liter)], and maximum follicle diameter (10.4 Ϯ 0.6 mm) on ultrasound were consistent with initiation of the study in the early follicular phase. There were no differences in laboratory or radiological parameters at baseline between CW and AAW.
Steroid infusion
AAW and CW achieved similar E2 and P levels during the infusion (Table 1) . There was an incremental rise in E2 to an average plateau of 288.2 Ϯ 13.9 pg/ml (1057.7 Ϯ 51.4 pmol/liter) during the final infusion interval, and P levels reached a plateau of 1.8 Ϯ 0.11 ng/ml (5.7 Ϯ 0.3 nmol/liter). There were no differences in the mean E2 or P levels at each iv steroid concentration between AAW and CW (Table 1) , nor were there any differences in the rise in E2 or P between infusion increments.
Negative feedback
As E2 levels began to rise, LH and FSH decreased by 56 Ϯ 3 and 59 Ϯ 2%, respectively ( Fig. 1 and Table 1 ). The FSH nadir was delayed (58.7 Ϯ 2.2 h) compared with that of LH (32.7 Ϯ 2.1 h), with no difference in AAW compared with CW. There were no racial differences in the LH or FSH nadir when expressed in absolute terms or as a percentage decrease from baseline (Table 1) .
Positive feedback
With continued E2 and P administration, the initial decline in gonadotropins was reversed, and LH and FSH levels began to increase (Fig. 1) at an average time of 57.4 Ϯ 1.7 and 75.6 Ϯ 3.3 h, respectively, with no differences between AAW and CW. The magnitude of the positive feedback response for LH and FSH was also similar between the two groups in terms of both peak LH and AUC (Table 1) . Positive feedback occurred in the absence of a change in follicle diameter (0.2 Ϯ 0.8 mm), as expected in the face of an exogenous steroid infusion.
Discussion
We have previously shown that AAW have 20% higher E2 levels than CW during the late follicular phase of the menstrual cycle but similar LH and FSH levels (4). We hypothesized that this pattern may reflect decreased responsivity to estrogen-positive feedback. However, using a sex steroid infusion protocol that precisely controls the dose and duration of estrogen exposure, we have now demonstrated that there are no racial differences in estrogenpositive feedback dynamics. The current studies instead suggest that the central components of the reproductive axis, responsible for generating the LH surge, are relatively insensitive to E2 differences of the magnitude previously identified in regularly cycling AAW and CW (4). Our findings are consistent with the concept of an "E2 threshold" whereby the LH response to E2 increases progressively until a particular level of E2 is reached. In support of this conclusion, in ovariectomized rats treated with varying concentrations of E2 and low levels of P, a high physiological dose of E2 did not augment the height of the LH surge or increase the number of pituitary E2 nuclear receptors beyond what was observed with lower physiological doses (11) . In addition, in regularly cycling women treated with increasing concentrations of E2 benzoate, the LH responses to exogenous GnRH increased between E2 concentrations of 91 pg/ml (334 pmol/liter) and 195 pg/ml (716 pmol/liter) but plateaued thereafter, despite further increases in E2 (12) . The concept of an E2 threshold is also supported by studies in postmenopausal women receiving a range of transdermal E2 doses to achieve E2 concentrations of 185-520 pg/ml (679 -1908 pmol/liter). Although LH surges were seen most consistently in conjunction with higher serum E2 levels, the height, timing, and duration of induced surges was not influenced by E2 concentration (13) .
By controlling E2 and P levels in AAW and CW, the current studies also demonstrate that there are no racial differences in estrogen-negative feedback dynamics as expected from the similar gonadotropin and E2 levels in AAW and CW in the early and mid-follicular phases in normally cycling women (4). We cannot however, exclude the possibility that attenuated negative feedback during the luteal phase accounts for the increased FSH during the luteal-follicular transition identified in African mothers of dizygotic twins (14) .
In conclusion, we found no evidence of decreased LH or FSH responsivity to estrogen-positive feedback in AAW compared with CW using a controlled steroid infusion protocol. In the context of our previous studies demonstrating increased E2 but similar LH and FSH levels in AAW compared with CW, these studies support in vitro and in vivo studies that have suggested the importance of an E2 threshold in generating the preovulatory surge and indicate that this threshold is exceeded in regular menstrual cycles of both AAW and CW.
